Pharmacodynamics Flashcards

1
Q

What is the most common target for human drugs?

A

Proteins! 95% of drug targets in the human body are proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What types of proteins are most commonly targeted by drugs?

A

Kinase proteins and GPCRs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How could a drug affect a receptor protein?

A

It can act as an agonist (activate the receptor. could be a partial agonist (not able to elicit full response) or a full agonist), an antagonist (inhibit the receptor. could be competitive, non-competitive, or an irreversible inhibitor), or an inverse agonist (binding reduces basal activity of receptor and can, in some cases, also act as a competitive inhibitor.
An agonist would bind to the receptor protein as if it were the natural ligand. A competitive inhibitor would bind to the receptor as if it were the natural ligand. A non-competitive inhibitor would bind to an allosteric site. An irreversible inhibitor would bind and “lock” to the ligand site. An inverse agonist could do either.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How could a drug affect an ion channel protein?

A

It could physically block the ion channel’s opening. It could also modify the ion channel’s ability to pass ions through by increasing or decreasing the channel’s probability of being open (shape change caused by binding of drug)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How could a drug affect an enzyme protein?

A

It could use the enzyme to create an active form of the drug. It could act as a false substrate for the enzyme. It could block the enzyme from functioning. It could lead to the phosphorylation or dephosphorylation of the enzyme, activating or deactivating the enzyme.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How could a drug affect a carrier protein?

A

The drug could use the carrier protein to get into a cell, or it could inhibit the carrier protein from letting other stuff into the cell.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is non-competitive inhibition?

A

The inhibitor binds to an allosteric site on the protein, which decreases its function but does not decrease the ability of substrate to bind to the protein. The Vmax decreases and Km does not change in MM graphs. In Hill dose response graphs the Kd would be unchanged but the max response would decrease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is competitive inhibition?

A

The inhibitor binds to the protein where its natural ligand would have bound. This keeps the substrate from binding. When a substrate is able to bind, the outcome is normal. Competitive inhibition changes Km (increases) but does not change Vmax

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is irreversible non-competitive inhibition?

A

The inhibitor binds and locks onto the protein. Nothing else can bind that protein, and it is a permanent change. This would increase Km and not change Vmax, because presumably as long as you can find an open enzyme you’d be able to get the optimal response from that enzyme.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How does competitive inhibition impact a michaelis menten or Hill dose-response curve?

A

Increase Km (Kd in Hill), no change in Vmax (Response in Hill)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is an antagonist?

A

A drug that stops agonists (anti-agonist) from engaging fully or at all with a target protein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is an agonist?

A

A drug that stimulates the activity of a target protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is an inverse agonist?

A

A drug that stops basal receptor activity (receptors can be randomly active even when not bound with ligands) while allowing agonists to still bind (or if it’s a competitive inhibitor it would also be an antagonist). Inverse agonists are not called antagonists because they have an independent effect on receptors, where agonist can only block other ligands from doing their thing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why do inverse agonists impact receptor activity?

A

Many of our receptors have natural levels of activity even when not bound to their signaling molecules. This allows for a sustainable “base” level of activity in the cell (you can’t survive without some PKA being active even when glucagon isn’t around). Inverse agonists interrupt that basal activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does noncompetitive inhibition impact dose-response (Hill) or michaelis menten graphs?

A

It would decrease Vmax (or maximum response in Hill) while not affecting Km (Kd). This is true for irreversible binding as well, because any enzyme that’s still functional would be able to reach maximum velocity. It’s assuming you don’t bind enough enzymes to totally shut the system down though.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is Kd?

A

Kd is the drug concentration at which 50% of receptors are occupied. A lower Kd means your drug has a stronger binding affinity for the receptor. A higher Kd means you have a lower binding affinity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are ED50, TD50, and LD50 in dosage response curves?

A

ED50 is the drug dose at which you get 50% of maximal therapeutic impact. TD50 is the drug dose at which you get 50% of the maximal toxic effect. LD50 is the dosage at which 50% of people using the drug die.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the axes for a dosage response curve?

A

y axis = %maximum response.

x axis = drug concentration. it is often logarithmic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Which axis in dose response or michaelis menten curves is often on a logarithmic scale?

A

X axis (drug concentration). This is because sometimes it takes magnitudes larger dosages to get an appreciable change in effect, especially as you get towards the maximal response. Your graph would be gargantuan with a big asymptotic line if you did a linear x-axis. Doing a logarithmic X-axis will make the graph look like an S

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are full agonists? Partial agonists? Neutral antagonists? Inverse agonists?

A

Full agonists are agonists which, when flooded in a system, can elicit a maximal response from the receptor protein. Partial agonists are agonist which, when flooded in a system, can only elicit a partial response. Neutral antagonists are antagonists which inhibit receptor activity with other ligands without causing any increase in activity (some antagonists block ligands but cause a minor amount of activity themselves). An inverse agonist cuts back the basal activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How could a partial agonist be used to treat an addiction?

A

The partial agonist will not be able to create as strong a response. Assuming that you use all the receptors (which is fairly accurate in overdose situations), added partial agonists will compete away some of the full agonists. Your end response curve would be something in between the partial agonist response curve and the full agonist response curve

22
Q

What is the most effective form of receptor inhibition?

A

Probably a competitive inhibitor/inverse agonist. It would stop substrates from binding AND would decrease basal activity.

23
Q

What is a natural agonist?

A

The ligand that would naturally bind to a receptor in the body. The opioid receptor in the body is naturally bound with endorphins. Illicit drugs would be ingested agonists that just happen to use the same receptor.

24
Q

What is the Hill-Langmuir equation?

A

Y=[D]/(Kd + [D])

25
Q

What is the Michaelis Menten equation?

A

V=Vmax*[S]/(Km+[S])

26
Q

What is drug potency?

A

The ability of a drug to reach its maximal impact quickly.

27
Q

What is drug efficacy?

A

The ability of a drug to reach a high level of response.

28
Q

Draw what a potent but ineffective drug would look like compared to potent & effective drug and a non-potent but effective drug.

A

Potent and ineffective would have a really small Kd and a small total effect size. (low maximal response)
potent & effective would be small Kd and big maximal response. non-potent but effective drug would have a large Kd and a large maximal response.

29
Q

What is signal amplification? How does it impact pharmacodynamics?

A

Signal amplification alludes to the fact that one signal molecule could lead to more than one “unit” of physiological response. A single signal molecule could cause the release of 3 cAMP, which activate 3 PKA, which activate 30 enzymes. It means you don’t always need to bind 100% of receptors to get a maximal physiologic response.

30
Q

Where does a competitive inhibitor bind to a receptor protein? What about non-competitive?

A

The ligand binding site.

The allosteric binding site.

31
Q

How would you create a dose response curve for discrete data?

A

You can’t be 30% asleep, or 30% without stomach ulcers. So you look at a population, and say 30% of people will be asleep at this concentration of the drug. For the population it’s continuous (cumulative distribution), for the individual it is discrete.

32
Q

What kind of data is required for an individual dose-response curve?

A

Continuous!

33
Q

What is quantal data?

A

Discrete data

34
Q

What is the therapeutic window?

A

The range of drug concentration from 1% therapeutic effect to 1% toxic effect. This is the range in which you get a therapeutic effect without an toxicity. The “safe” region.

35
Q

What is the therapeutic index? In what situations is it a poor measure of drug usability?

A

50% Toxic Dose / 50% Therapeutic Dose (TD50/ED50)
or LD50/ED50.
TI tells you how much “wiggle room” you have with your treatment. You want a high TI (high TI means there’s little chance of causing toxic effects at therapeutic concentrations). It is a poor measure of drug usability if the Therapeutic and Toxic/Lethal dose response curves are not sloped the same.

36
Q

Why would the shape of a drug’s dose response curve differ for its therapeutic and toxic/lethal effects?

A

If you had a response curve that was not the traditional S shape, you could get more or less of a toxic effect earlier. If it’s less that’s no trouble. But if the toxic effect begins much sooner than expected, you could be treating at a therapeutic concentration that was also toxic to the body. This happens when toxicity and therapy are achieved through different mechanisms.

37
Q

What is mechanism-based toxicity?

A

The mechanism for drug therapy is the same mechanism for toxicity. The toxic and therapeutic dose-response curves would be identical in shape

38
Q

What is off-target toxicity?

A

Off target toxicity is when you have a different therapeutic and toxic mechanism of action. This means the dosage curves could look nothing alike.

39
Q

What is the certain safety factor? Why is it valuable?

A

Certain safety factor is a more strict way to evaluate therapeutic vs. toxic dosages. CSF = [Drug at 1% lethal]/[Drug at 99% therapeutic]. You want a higher value.

40
Q

What is drug synergy?

A

When two drugs interact in a way that causes a net response above what you would expect from adding each independently.

41
Q

What would antagonistic drug interactions look like?

A

You’d have less of a total response than you would expect if you added the two drugs’ independent effects together.

42
Q

What would additive drug interactions look like?

A

You get the total response you’d expect from summing the individual responses

43
Q

What is potentiation?

A

When one drug “helps” or “hinders” another drug’s response without acting through the same mechanism. Maybe it decreases the metabolism of the drug in the liver.

44
Q

What is tolerance/desensitization?

A

A decreased response to drug over time. Happens with nicotine, opioids, caffeine

45
Q

What is tachyphylaxis?

A

Short-term decreased response to drug over time.

46
Q

What are ways that tolerance can develop from a biochemical viewpoint?

A

Receptors can be uncoupled from their signaling cascade. The receptor can be pulled off the membrane (internalized) and left in an endosome (membrane bound compartment). Or the receptor can be pulled off the membrane and digested by lysosomes (called down-regulation)

47
Q

What is biochemical compensation?

A

Eventually, if enough synthetic signal molecule is present in the body there will be decrease in naturally produced ligand. Alternatively you could have an increase in number of receptors but a decrease in response from each receptor

48
Q

How would long-term desensitization impact a dose-response curve?

A

Increase ED50 (Kd, Km) maybe decrease maximal response (Vmax)

49
Q

How would a GPCR induce signal amplification?

A

GPCR activated by single signal molecule. It causes the release of multiple cAMP. Each cAMP induces changes in multiple kinases. Each kinase acts on multiple molecules. Something like that.

50
Q

What would a low certain safety factor tell you?

A

The drug could be toxic/lethal at therapeutic doses

51
Q

What would a high certain safety factor tell you?

A

The drug should be safe to use at therapeutic doses.

52
Q

What would a low therapeutic index tell you?

A

The therapeutic dose-response curve was close to the toxic dose-response curve